Core Insights - Yidu Technology reported a total revenue of 358 million yuan for the six months ending September 30, 2025, representing a year-on-year growth of 8.7% [1] - The company's adjusted EBITDA doubled compared to the same period last year, reaching approximately 54 million yuan, indicating significant improvements in profitability and operational efficiency [1] Business Segments - The AI for Medical segment generated revenue of 153 million yuan, reflecting a year-on-year increase of 14.6%. The company has provided solutions to 127 top hospitals and 44 regulatory bodies and policymakers in China [2] - The AI for Life Science segment achieved revenue of 138 million yuan, supporting the accelerated approval of several innovative drugs, including a world-first topical gel for infantile hemangioma and a new drug for chronic hepatitis B [2] - The AI for Care segment reported impressive performance with revenue of 66.67 million yuan, up 30.3% year-on-year. The company has maintained its leading position in the "Hui Min Bao" business in core cities, serving as the main operating platform for "Shenzhen Hui Min Bao" for three consecutive years and "Beijing Pu Hui Health Bao" for five years [2] - The company's diabetes digital therapy has expanded from initial pilot areas to additional locations, with over 22 million active trading users on the health management platform by the end of the reporting period [2] Technological Advancements - YiduCore, the company's core algorithm engine, has processed and analyzed over 1.3 billion patient visits and nearly 7 billion authorized medical records, covering more than 10,000 hospitals and creating a comprehensive disease knowledge graph [1]
医渡科技公布中期业绩：经调整EBITDA同比翻倍